| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8371292 | COVIS | Use of ciclesonide for the treatment of respiratory diseases |
Feb, 2028
(4 years from now) | |
Zetonna is owned by Covis.
Zetonna contains Ciclesonide.
Zetonna has a total of 1 drug patent out of which 0 drug patents have expired.
Zetonna was authorised for market use on 20 January, 2012.
Zetonna is available in aerosol, metered;nasal dosage forms.
Zetonna can be used as treatment of symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older. patent claims methods for treating a respiratory disease in a child.
The generics of Zetonna are possible to be released after 01 February, 2028.
Drugs and Companies using CICLESONIDE ingredient
Market Authorisation Date: 20 January, 2012
Treatment: Treatment of symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older. patent claims methods for treating a respiratory disease in a child
Dosage: AEROSOL, METERED;NASAL
ZETONNA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic